169366 ⎘
Investigating or analysing materials by specific methods not covered by groups -; Biological material, e.g. blood, urine ; Haemocytometers; Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors Immunosupressants
HEMOLYSIS AND DERIVATIZATION REAGENTS AND METHODS FOR DETERMINING LACTONE ANALYTES
#2ENHANCED LATERAL FLOW ASSAYS AND DEVICES FOR DETECTING ANALYTES IN BLOOD SAMPLES
#3REAGENT COMBINATION AND METHOD FOR DETECTING TARGET IMMUNOSUPPRESSANT IN WHOLE BLOOD WITHOUT CENTRIFUGATION
#4MASS SPECTROMETRIC QUANTITATION ASSAY FOR METABOLITES OF LEFLUNOMIDE
#5PRETREATMENT AGENT IN NON-AGGLUTINATION ASSAYS
#6BINDING COMPETITORS FOR USE IN MACROPHILIN-BINDING PHARMACEUTICAL ASSAYS AND METHODS OF USE THEREOF
#7SANDWICH ASSAY FOR SMALL MOLECULES
#8Mass spectrometric quantitation assay for metabolites of leflunomide
#9ASSAY METHOD FOR POINT OF CARE QUANTIFICATION OF AN IMMUNOPHILIN-BINDING IMMUNOSUPPRESSANT DRUG
#10CYCLOPHOSPHAMIDE ANALOGS FOR USE AS IMMUNOGENS AND ASSAY CONJUGATES FOR AN IMMUNOASSAY OF CYCLOPHOSPHAMIDE AND IFOSFAMIDE
#11Pretreatment agent in non-agglutination assays
#12Detection kit for detecting immunosuppressors in whole blood by high performance liquid chromatography-tandem mass spectrometry and detection method thereof
#13Mass spectrometric quantitation assay for metabolites of leflunomide
#14NOVEL USE OF REGULATORY T CELL-SPECIFIC SURFACE PROTEIN LRIG-1
#15Method for measuring organic matter in blood by using LDI-MS, and device therefor
#16METHODS FOR DIAGNOSING OR TREATING POST-TRAUMATIC STRESS DISORDER, AND COMPOSITIONS THEREFOR
#17Binding competitors for use in macrophilin-binding pharmaceutical assays and methods of use thereof
#18Use of regulatory T cell-specific surface protein LRIG-1
#19Method of testing a blood for macrolide immunosuppressant
#20Sandwich assay for small molecules
#21NMR SYSTEMS AND METHODS FOR THE RAPID DETECTION OF ANALYTES
#22METHODS FOR DETERMINING A DRUG DOSING REGIMEN
#23Sandwich assay design for small molecules
#24Test strip and kit for testing mycophenolic acid and preparation method of test strip
#25SCREENING METHOD FOR BLOOD IgA PRODUCTION INHIBITOR OR FOR PROPHYLACTIC OR THERAPEUTIC AGENT AGAINST DISEASES CAUSED BY EXCESSIVE IgA IN BLOOD
#26Extraction reagent of immunosuppressant drug for immunoassays
#27Mass spectrometric quantitation assay for metabolites of leflunomide
#28Pretreatment agent in non-agglutination assays
#29LC-MS configuration for purification and detection of analytes having a broad range of hydrophobicities
#30NOVEL USE OF REGULATORY T CELL-SPECIFIC SURFACE PROTEIN LRIG-1
#31Cyclophosphamide analogs for use as immunogens and assay conjugates for an immunoassay of cyclophosphamide and ifosfamide
#32Generic pretreatment reagents for analyte determinations
#33Use of regulatory T cell-specific surface protein LRIG-1
#34PRETREATMENT AGENT IN NON-AGGLUTINATION ASSAYS
#35NMR SYSTEMS AND METHODS FOR THE RAPID DETECTION OF ANALYTES
#36Compounds and methods for the detection of methotrexate
#37Cyclophosphamide analogs for use as immunogens and assay conjugates for an immunoassay of cyclophosphamide and ifosfamide
#38SANDWICH ASSAY FOR SMALL MOLECULES
#39METHOD TO DETECT BLOOD CREATININE AND AN IMMUNOSUPPRESSIVE DRUG
#40Mass spectrometric quantitation assay for metabolites of leflunomide
#41Universal assay for determining the quantity of TNFα inhibitory drugs and their corresponding anti-drug-antibodies
#42SANDWICH ASSAY DESIGN FOR SMALL MOLECULES
#43Systems and methods for the measurement of tacrolimus in oral fluids by liquid chromatography tandem mass spectrometry
#44LC-MS configuration for purification and detection of analytes having a broad range of hydrophobicites
#45Method to optimize the treatment of patients with biological drugs
#46BIOLOGICAL CHARACTERIZATION OF A GLATIRAMER ACETATE RELATED DRUG PRODUCT USING MAMMALIAN AND HUMAN CELLS
#47PRETREATMENT AGENT IN NON-AGGLUTINATION ASSAYS
#48Mass spectrometric quantitation for metabolites of leflunomide
#49Anti-tofacitinib antibodies and uses thereof for drug monitoring
#50Methods for detecting antibodies
#51Use of regulatory T cell-specific surface protein LRIG-1
#52Compositions and methods comprising binding proteins for adalimumab
#53Methods for determining ligand binding to a target protein using a thermal shift assay
#54DEVELOPMENT OF SPECIFIC IMMUNOASSAY CRITICAL REAGENTS FOR PHARMACOKINETIC ASSESSMENTS OF PEPTIDE POLYMERS IN PRECLINICAL AND CLINICAL MATRICES
#55Compounds and methods for determination of FKBP-binding immunosuppressant drugs
#56Methods of evaluating peptide mixtures
#57Methods for determining ligand binding to a target protein using a thermal shift assay
#58Preparation of anti-PEG antibody expressing cell and application thereof
#59Methods of evaluating diethylamide in peptide mixtures for the preparation of glatiramer acetate
#60Determination of total analyte concentration
#61NMR systems and methods for the rapid detection of analytes
#62NMR systems and methods for the rapid detection of analytes
#63Sandwich assay for immunosuppressant drugs
#64Methods for detecting antibodies
#65Diagnostic test for the detection of a molecule or drug in whole blood
#66Maintaining Antibody-Binding Activity Of Immunosuppressant Drug Conjugates
#67Mass spectrometric quantitation assay for metabolites of leflunomide
#68METHODS FOR MONITORING IMMUNOSUPPRESSANT DRUG LEVELS, RENAL FUNCTION, AND HEPATIC FUNCTION USING SMALL VOLUME SAMPLES
#69CYCLOSPORIN CONJUGATES
#70Assay for immunosuppressant drugs
#71Method of identifying patients not suitable for high-dose cyclophosphamide treatment
#72Methods for detection of hydrophobic drugs
#73Assay for analytes using multiple receptors
#74ANTI-POLYETHYLENE GLYCOL ANTIBODY EXPRESSING CELL QUANTIFY ANY FREE POLYETHYLENE GLYCOL AND POLYETHYLENE GLYCOL-DERIVATIZED MOLECULES
#75Risk assessment for cutaneous adverse drug reactions from antiretroviral agent
#76Method of Risk Management for Patients Undergoing Natalizumab Treatment
#77ANALYSIS OF MYCOPHENOLIC ACID IN SALIVA USING LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY
#78Method for evaluation of quality of blood sample
#79Methods for detection of cyclosporin A
#80Non-denaturing lysis reagent
#81Methods for detection of hydrophobic drugs
#82Immunosuppressant drug extraction reagent for immunoassays
#83Immunosuppressant Target Proteins
#84Vm23 and Vm24, two scorpion peptides that block human T-lymphocyte potassium channels (sub-type Kv1.3) with high selectivity and decrease the in vivo DTH-responses in rats
#85Method and device for processing a biological fluid for analyte determination
#86Methods for detection of immunosuppressant drugs
#87Detection of false results in assays
#88Method and Apparatus for Analyzing Bioprocess Fluids
#89Tacrolimus standard and methods of using same
#90Assay for immunosuppressant drugs
#91Diagnostic test for the detection of a molecule or drug in whole blood
#92Methods for Monitoring Immunosuppressant Drug Levels, Renal Function, and Hepatic Function Using Small Volume Samples
#93Methods to measure immunosuppressive tacrolimus, sirolimus, and cyclosporin a complexes in a blood sample
#94Methods of evaluating diethylamide in glatiramer acetate
#95Method of risk management for patients undergoing Natalizumab treatment
#96METHODS FOR DETECTION OF CYCLOSPORIN A
#97Methods for detection of hydrophobic drugs
#98Method and apparatus for detection of analyte using an acoustic device
#99Method and apparatus for therapeutic drug monitoring using an acoustic device
#100Compositions and methods comprising binding proteins for adalimumab
#101Expression analysis of FKBP54 in the diagnosis and treatment of prostate cancer
#102Methods for detection of immunosuppressant drugs
#103ANALYSIS OF MYCOPHENOLIC ACID IN SALIVA USING LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY
#104Immunoassays exhibiting reduced cross-reactivity with hydrophobic drug analyte metabolites
#105MONITORING CYCLOSPORINE IN SALIVA
#106Non-denaturing lysis reagent
#107HOMOGENEOUS DOUBLE RECEPTOR AGGLUTINATION ASSAY FOR IMMUNOSUPPRESSANT DRUGS
#108Method and device for processing a biological fluid for analyte determination
#109Immunosuppressant drug extraction reagent for immunoassays
#110Tacrolimus standard and methods of using same
#111DETERMINATION OF CONCENTRATION OF FK778 BY COMPETITIVE IMMUNOASSAY
#112Methods of identifying immunoregulatory agents, immunoregulatory agents, and uses thereof
#113DETERMINATION OF CONCENTRATION OF FK778 BY COMPETITIVE IMMUNOASSAY
#114Method and apparatus for analyzing bioprocess fluids
#115Anti fk778antibodies and high sensitive immunoassay methods
#116Determination of concentration of FK778 by competitive immunoassay
#117Assay for the detection of rapamycin and rapamycin analogs
#118Receptor on the surface of activated T-cells: ACT-4
#119Single receptor assays for immunosuppressive drugs
#120Methods to measure immunosuppressive tacrolimus, sirolimus, and cyclosporin A complexes in a blood sample
#121Compositions and methods for detection of sirolimus
#122Extracting reagent for hydrophobic analyte in whole blood
#123Modulators of leukocyte activation, compositions and methods of use
#124Immunoassays for everolimus
#125Methods and kits for the determination of sirolimus in a sample
#126Reagents and methods for mycophenolic acid immunoassay
#127Immunoassays for everolimus
#128Reagents for assays for ligands
#129Modulators of B-lymphocyte activation, myosin-1F compositions and methods of use
#130Method and composition useful for determining FK 506
#131Expression analysis of FKBP54 in assessing prostate cancer therapy
#132Immunosuppressant target proteins